RT Journal Article
SR Electronic
T1 Differential transcript usage unravels gene expression alterations in Alzheimer’s disease human brains
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.19.20038703
DO 10.1101/2020.03.19.20038703
A1 Marques-Coelho, Diego
A1 da Cruz Carvalho, Lukas Iohan
A1 de Farias, Ana Raquel Melo
A1 ,
A1 Lambert, Jean-Charles
A1 Costa, Marcos Romualdo
YR 2020
UL http://medrxiv.org/content/early/2020/04/16/2020.03.19.20038703.abstract
AB Alzheimer’s disease (AD) is the leading cause of dementia in aging individuals. However pathophysiological processes involved in the brain are still poorly understood. Among numerous strategies, a comprehensive overview of gene expression alterations in the diseased brain has been proposed to help for a better understanding of the disease processes. In this work, we probed the differential expression of genes in different brain regions of healthy and AD adult subjects using data from three large studies: MAYO Clinic; Mount Sinai Brain Bank (MSBB) and ROSMAP. Using a combination of differential expression of gene (DEG) and isoform switch analyses we provide a detailed landscape of gene expression alterations in the temporal and frontal lobes, harboring brain areas affected at early and late stages of the AD pathology, respectively. Next, we took advantage of an indirect approach to assign the complex gene expression changes revealed in bulk RNAseq to individual cell types of the adult brain. This strategy allowed us to identify cell type/subtype specific isoform switches in AD brains previously overlooked. This was the case, for example, for the AD causal gene APP and the risk gene BIN1, which presented isoform switches with potential functional consequences in neuronal cells. Altogether, our work proposes a novel integrative strategy to analyze RNAseq data in AD based on both gene/transcript expression and regional/cell-type specificities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was co-funded by the European Union under the European Regional Development Fund (ERDF) and by the Hauts de France Regional Council (contrat_18006176), the MEL (contract_2016_ESR_05), and the French State (contract_2018-3-CTRL_IPL_Phase2) to MRC. This work was also funded by the Lille Métropole Communauté Urbaine and the French government’s LABEX DISTALZ program (Development of innovative strategies for a transdisciplinary approach to Alzheimer’s disease) to JCL. DMC and LICC are supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) scholarships.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is publicly available